ACTRN12624000007538招募中Unknown
Prospective Longitudinal Assessment of Treatment options for Young Patients with Upper airway Structural abnormalities (PLATYPUS): a pilot study
Perth Children's Hospital0 个研究点目标入组 120 人开始时间: 2024年1月9日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Diagnosis
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- o limit 至 6 Months（—）
- 性别
- All
入选标准
- •Patients up to 6 months of age/6 months corrected age (if born premature) who have been referred to the Ear, Nose and Throat (ENT) team at PCH for management of suspected laryngomalacia will be recruited.
排除标准
- •Children with any syndromic features or neuromuscular conditions
- •Children with known significant cardiac disease
- •Children unable to complete at-home oximetry
- •Families without a sufficient level of English to be consented.
研究者
相似试验
已完成
4 期
Prospective longitudinal outcome study assessing the use of REGENOSS for attaining spinal fusion in patients requiring single level Posterior Interbody Fusion (PLIF) in the lumbar spine.spondylolisthesisNL-OMON47404Finceramica24
已完成
4 期
Prospective longitudinal outcome study assessing the use of BonAlive bioactive glass for attaining eradication of osteomyelitis and stimulation of bone healing in patients requiring surgery in osteomyelitic bone defects.osteomyelitisNL-OMON46331Medisch Universitair Ziekenhuis Maastricht24
已完成
不适用
Prospective observational study of the treatment and prognosis in patients with relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation.Adult T-cell leukemia-lymphomaJPRN-UMIN000009251JSCT30
招募中
不适用
Prospective observational study of the treatment and prognosis in patients with previously untreated indolent B cell lymphomaIndolent B-cell Non-Hodgkin's lymphomaJPRN-UMIN000010175Fukuoka Lymphoma Study Group200
进行中（未招募）
不适用
Prospective observational study for Treatment resistance related gene screening using plasma circulating tumor DNA in the third generation EGFR-TKI Osimertinib therapyJPRN-jRCTs031180051Tamiya Akihiro180